Merck: Merck and Epitopea Join Forces to Identify Unknown Tumor Antigens
The agreement, in which Merck will pay the biotech an undisclosed initial sum to license drugs targeting a solid tumor, could net Epitopea up to $300 million down the line.
Read full article »
Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.
Read more